Pharmaceutical SOE Holding Signs MoU with Four Global Companies at G20 SoE Conference 2022



Left-right : Bugi Riagandhy (Director of Life Insurance InHealth Indonesia), Soleh Ayubi (Director of Transformation and Digital of PT Bio Farma (Persero), Pahala Mansyuri (Vice Minister of BUMN I), Honesti Basyir (President Director of PT Bio Farma (Persero), Yiming Yao (CEO of Suzhou Ronnsi Pharma Co.Ltd)

(Nusa Dua 18/10) Holding SOE Pharmaceutical Bio Farma, carried out four signing of cooperation with four global Healthcare Companies on the sidelines of the G20 State-owned-Enterprise (SoE) International Conference & Expo2022, which was held on 17 - 18 October 2022, in Nusa Dua Bali.

In order to collaborate on the development of a Supply Agreement on Active Pharmaceutical Ingredients (API) for Enoxaparin products from Ronsi, which will be formulated at Bio Farma, where this product is targeted to be sold for the export market, Bio Farma and Suzhou Ronnsi Pharma Co., Ltd (Ronsi) agreed to sign. The signing was done by President Director Ronsi Yiming Yao and President Director Honesti Basyir of Bio Farma.

The second signing is between Bio Farma and ConnectedLife Health Singapore in cooperation in commercializing preventive care services in Indonesia. It was signed by the President Director of Bio Farma, Honesti Basyir, with ConnectedLife Health Singapore CEO Daryl Arnold.

The signing of the third MoU between Bio Farma and InHealth Indonesia Life Insurance was carried out by Bio Farma's Director of Transformation and Digital Soleh Ayubi., Ph.D., and Marketing Director Bugy Riagandhy. This MoU relates to developing preventive care system services to

monitor the health and physical activity of MANDIRI INHEALTH participants using Medwell services and home care services to connect to all of Bio Farma's digital health platforms.



Left-right: Mohd. Hareeff Bin Muhammed (CEO of Pantai Premier Pathology), David Utama (President Director of PT Kimia Farma, Tbk), Pahala Masyuri I (Vice Minister of BUMN I), Honesti Basyir (President Director of PT Bio Farma (Persero), Daryl Arnold (CEO Connected LifeSingapore).

In addition, PT Kimia Farma Tbk as a member of Holding BUMN Pharmaceuticals, Tbk also signed an MoU with Pantai Premier Pathology Sdn Bhd Kimia Farma for cooperation in mentoring and technical knowledge support for the development of laboratory services. With the implementation of this collaboration, Kimia Farma can further improve the quality and services of its laboratory.

The entire signing was witnessed by the Deputy Minister of BUMN I, Pahala Nugraha Mansury. During his press statement, he said that Indonesia had learned from the Covid-19 pandemic and how we could avoid it if there is another pandemic to be able to strengthen health infrastructure. "Indonesia currently still has a large enough dependence on other countries, to be able to ensure that the Indonesian people receive health services such as drugs, vaccines, to avoid a pandemic. Therefore today (18/10) the Bio Farma group signed a cooperation agreement to strengthen health infrastructure in Indonesia," said Pahala.

Pahala continued that the IndoVac vaccine, a Covid-19 vaccine made by Bio Farma, is an example of capacity building in the health industry, all of which we collaborate with outside Indonesia.

Meanwhile, the President Director of Bio Farma, Honesti Basyir, explained that the company has a large enough production capacity to produce 20 million doses of Indovac for the government's booster program and then grow that number to 40 million doses.

"Future production of the IndoVac vaccine will have a total capacity of 120 million doses, which will be adjusted for demand. Since instructed by the Ministry of SOEs, the IndoVac vaccine will be used globally as the moment for Indonesia to assist in containing the pandemic is now, given that there are still shortages of Covid-19 vaccines in the global supply, "Honesti added.

Additionally, at the end of September 2022, Bio Farma just finalized a coorperation agreement for the blood product Recombinant Factor VIII with the British pharmaceutical company ProFactor Pharma in order for Bio Farma to eventually master the technology for the treatment of hemophilia or blood clots.

"This is one of the non-communicable diseases that Bio Farma handles, but it is quite dangerous and needs severe handling," said Honesti.

---00ed00---

For media information, contact:

Rifa Herdian

Corporate Secretary & Investor Relation PT Bio Farma (Persero)

Ph 08125428844

Email : rifaherdian@biofarma.co.id